Abstract
Thirty-two patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (1.50 gm/m2 daily × 5 days) with uroprotective mesna in a phase II study. Eighteen patients were previously untreated. Of 28 evaluable patients, two (7%) had partial remissions lasting 2+ and 6+ months. Toxicity was predominantly myelosuppression with a median WBC nadir of 1.8 cells/ul. Seven patients required hospitalization for nadir sepsis. Ifosfamide has minimal activity in esophageal cancer and causes severe myelosuppression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Calvin M: The comparative pharmacology of cyclophosphamide and ifosfamide. Sem Onc 9 (4): Suppl 1, 2–7, 1982
Morgan LR, Harrison EF, Hawke JE, Hunter HL, Constanzi JJ, Plotkin O, Tucker WG, Worrall AM: Toxicity of single versus fractionated dose ifosfamide in non-small cell lung cancer: a multi-center study. Sem Onc 9 (4): Suppl 1, 66–70, 1982
Klien HO: Therapeutic effects of single push or fractionated injections of cyclophosphamide or ifosfamide combined with mesna. Cancer Treat Rev 10: Suppl A, 83–92, 1983
Scheulen ME, Niederle N, Bremer K, Schutte J, Seeber S: Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: Results of a clinical phase II study with 151 patients. Cancer Treat Rev 10: Suppl 1, 93–101, 1983
Antman KH, Montella D, Rosenbaum C, Schwen M: Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 69(5):499–504, 1985
Constanzi JJ, Morgan LR, Hokanson J: Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung. Sem Onc 9(4): Suppl 1, 61–65, 1982
Loehrer Sr PJ, Birch R, Kramer BS, Greco FA, Einhorn LH: Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: A Southeastern Cancer Study Group Trial. Cancer Treat Rep 70(7):919–20, 1986
Meanwell CA, Mould JJ, Blckledge G, Lawton FG, Stuart NS, Kavanagh J, Latief TN, Spooner D, Chetiyawardana AD: Phase II study of ifosfamide in cervical cancer. Cancer Treat Rep 70(6):727–30, 1986
Loehrer Sr PJ, Einhorn LH, Williams SD: VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 4(4):528–36, 1986
Wheeler BM, Loehrer PJ, Williams SD, Einhorn LH: Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4(l):28–34, 1986
Hunter HL, Harrison EF: The anticancer spectrum of ifosfamide. Sem Onc 9(4): Suppl 96–100, 1982
Kelsen DP, Cvitkovic E, Bains M: cis-Dichlorodiammineplatinum (II) and bleomycin in the treatment of esophageal carcinoma. Cancer Treat Rep 62: 1041–1046, 1978
Kelsen DP: Chemotherapy of esophageal cancer. Sem Onc 11(2):159–168, 1984
Sternberg C, Kelsen D, Dukeman M, Leichman L, Heelan R: Carboplatin: A new platinum analog in the treatment of epidermoid carcinoma of the esophagus. Cancer Treat Rep 69:1305–1307, 1985
Loehrer PJ, Williams SD, Einhorn LH, Ansari R: Ifosfamide: An active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 3:347–372, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nanus, D.M., Kelsen, D.P., Lipperman, R. et al. Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity. Invest New Drugs 6, 239–241 (1988). https://doi.org/10.1007/BF00175406
Issue Date:
DOI: https://doi.org/10.1007/BF00175406